Bevacizumab Results Offer Support for Upfront Therapy | Page 2

Ben Leach
Published Online: Tuesday, February 5, 2013
However, Cloughesy said that another candidate, an immunotherapy agent called rindopepimut (CDX-110), looks promising. Celldex Therapeutics, the manufacturer of rindopepimut, is currently enrolling patients with newly diagnosed glioblastoma for a phase III study.

Cloughesy said one of the reasons rindopepimut seems particularly exciting is because it targets EGFRvIII, a variant of the endothelial growth factor receptor (EGFR), which occurs in approximately 20% to 30% of patients with glioblastoma.

“It’s not present in any other part of the body, which makes it a good target,” Cloughesy said.

The results of previous trials have been promising. The phase II ACTIII trial enrolled 65 patients who received rindopepimut as well as maintenance therapy with temozolomide. In that study, the median PFS was 12.3 months (P = .0088) and the median OS was 24.6 months (P <.0001), both of which were significantly higher than historical controls.

Additionally, the study found that patients with methylated O6-methylguanine- methyltransferase enzyme (MGMT) performed significantly better when compared with those patients who had nonmethylated MGMT. The median PFS was 17.5 months in the methylated MGMT patients (n = 25) compared with 11.2 months in the nonmethylated MGMT patients (n = 40; P = .0057). The median OS was 32.3 months in the methylated patients compared with 20.9 months in the nonmethylated patients (P = .0067).

“All previous data have shown that specific populations of patients tend to do much better when they receive this vaccine,” Cloughesy said.
Chinot O, Wick W, Mason W, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAglio. Neuro Oncol. 2012; 14:vi101-vi105. Abstract OT-3.

Online CME Activities
Free CME from PER
Cancer Summaries and Commentaries™: 2016 Conference Coverage: Advances in the Treatment of Genitourinary Cancers
Community Practice Connections™: 12th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
Advances in the Treatment of Metastatic Colorectal Cancer
Renal Cell Carcinoma: Recent Advances, New Questions
More Reading